EMA recommends conditional approval of GSK cancer drug

Monday 22 February 2010

The European Medicines Agency (EMA) has recommended approval of GlaxoSmithKline’s new angiogenesis inhibitor for renal cell cancer, Votrient (pazopanib), conditional on further proof of the drug’s effectiveness.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom